Genting Berhad's Earnings Recover, Shares Lag
Genting Berhad's Earnings Recover, Shares Lag
Genting Bhd (GENT MK) experienced a lacklustre year in terms of share price performance, despite a strong earnings recovery driven by increased visitor numbers at its Resorts World Genting and Resorts World Sentosa properties, as highlighted in Maybank Investment Bank's (Maybank) recent report today (July 15, Monday).
马来西亚云頂集团（Genting Bhd）股价表现平平，尽管5月银行投资银行（Maybank）近日发布的报告指出，由云顶高地和圣淘沙名胜世界的入场人数增加推动收益强劲复苏。
Maybank maintains a BUY rating on Genting Bhd (GENT MK) with a MYR5.84 SOP-TP. Analysts at Maybank believe the recent share price weakness, amidst a 2% decline year-to-date compared to an 11% increase in the FBMKLCI, is unjustified. They point to the robust earnings recovery nearing pre-COVID levels and the potential positive impact of a stronger Malaysian Ringgit (MYR) against the USD, historically beneficial for Genting's valuations.
马来亚银行维持买入评级，目标股价为5.84马币。马来亚银行的分析师认为最近股价的疲软不公平，尽管相比FBMKLCI指数上涨11%，股票今年以来已下跌2%。他们指出，强劲的盈利恢复接近疫情前水平，以及马币对美元的潜在正面影响对云顶休闲的估值有益且历史悠久。
Maybank notes that Genting Bhd (GENT MK) stands to benefit from a potential regulatory approval for TauRx's experimental drug by year-end, with a hypothetical valuation scenario of USD15 billion for TauRx underpinning a significant upside potential to their SOP-TP of MYR9.35.
马来亚银行指出，TauRx实验药物年底前有望获得监管批准，假设TauRx的估值场景为150亿美元，将为其9.35马币目标价提供巨大的上行潜力。
Investors keen on Genting Bhd (GENT MK) might find Maybank's optimistic outlook compelling, given the anticipated earnings rebound and potential catalysts from TauRx's drug approval, coupled with expectations of MYR appreciation against the USD.
对于云顶休闲感兴趣的投资者，可能会发现马来亚银行的乐观前景令人信服，预计盈利会反弹，并有TauRx药物批准的潜在催化剂，再加上亚洲货币兑美元的升值预期。